Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
25 April 2019 | Story Rulanzen Martin | Photo Rulanzen Martin
SAGV Conference
From left; Dr Cilliers van den Berg, Head of the German Section; Prof Marianne Zappen-Thomson, President of SAGV and Dr Akila Ahouli, representative from GAS.

As much as it was a conference on Germanistik (German Studies) it also highlighted the international footprint of the University of the Free State (UFS) and the important role of international and national academic collaborations. 

The German Section in the Department Afrikaans and Dutch; German and French at the UFS hosted the second conference of the Association of German Studies in Southern Africa (SAGV) and German Studies in Sub-Saharan Africa (GAS) from 15-18 April 2019 on the UFS Bloemfontein Campus. 

“We are very proud to be hosting the conference. It is an international conference with delegates from overseas who are all working in German Studies or to use the German term Germanistik,” said Dr Cilliers van den Berg, Head of the German Section at the UFS. 

Waiting room in Germanistik explored

Warteräume (waiting rooms) was the theme of the four-day conference with various research papers on the role and/or value of these waiting rooms within Germanistik. “It is the transitional areas, within Germanistik, on every conceivable level,” said Van den Berg. The conference was sponsored by the embassies of Germany, Austria and Switzerland, as well as the German Academic Exchange Service and the Goethe Institute of Johannesburg.

“When I look at the theme of the conference it is extremely exciting because it reminds me of Homi Bhabha’s Third Spaces, liminal spaces and the in-betweeners,” said Prof Heidi Hudson, Dean of the Faculty of The Humanities. 

UFS and internationalisation


“One of the concepts we actively embrace is that of internationalisation. Globally and nationally, internationalisation has become accepted as one of the critical processes advancing the core business of universities,” said Prof Francis Petersen, Rector and Vice-Chancellor of the UFS.

The delegates who attended the conference were from countries which included, among others, Ethiopia, Burkina Faso, Italy, Kenya, Germany and Namibia as well as delegates from the universities of Stellenbosch, Pretoria, Rhodes and North-West. 

“You represent a multifaceted culture that has enriched our global academic and cultural landscape over many years: great minds like Goethe, Kafka, Beethoven, Mozart, Freud, and Einstein,” said Prof Petersen.


News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept